ESR1 and breast cancer: OP-1250 (Palazestrant) is a complete agonist ER receptor (CERAN) that acts as a selective ER degrader (SERD) by inhibiting estrogen-driven transcriptional activity and reducing tumor growth and proliferation in ER+ BC cells.